Explained: Trump Signs Memorandum Pressuring Pharma Companies to Abide by Ad Laws
Background on the Memorandum
In July 2020, former President Donald Trump signed an executive memorandum aimed at ensuring pharmaceutical companies comply with advertising laws. The move was part of a broader effort to increase transparency in drug pricing and reduce costs for American consumers. The memorandum specifically targeted the disclosure of list prices for prescription drugs in direct-to-consumer (DTC) advertisements, a practice critics argue has long been opaque.
Key Provisions of the Memorandum
The memorandum directed the Department of Health and Human Services (HHS) to enforce stricter adherence to existing advertising regulations. Key requirements included:
- Price Transparency: Pharmaceutical companies must disclose the wholesale acquisition cost (WAC) of drugs in TV ads if the medication costs $35 or more per month.
- Enforcement Mechanisms: HHS was empowered to monitor compliance and impose penalties, including legal action, for violations.
- Public Accountability: The policy sought to pressure companies to justify high prices by making them visible to consumers upfront.
Rationale Behind the Policy
The Trump administration argued that disclosing drug prices in ads would empower patients to make informed decisions and foster competition. By highlighting high costs, the policy aimed to deter pharmaceutical companies from setting exorbitant prices. Officials also framed the measure as a step toward fulfilling broader promises to lower prescription drug prices, a key issue in the 2016 and 2020 elections.
Industry Reactions and Legal Challenges
Pharmaceutical companies and industry groups strongly opposed the measure, claiming it would confuse consumers. They argued that list prices do not reflect out-of-pocket costs for most patients due to insurance negotiations and rebates. In 2019, a federal court had struck down a similar rule proposed by HHS, ruling that the agency lacked statutory authority to mandate price disclosures. The 2020 memorandum faced similar legal scrutiny, with opponents asserting it overstepped regulatory boundaries.
Political and Regulatory Context
The memorandum bypassed traditional rulemaking processes, reflecting the administration’s preference for swift executive action. Critics viewed it as a political maneuver ahead of the 2020 election rather than a substantive solution to high drug prices. However, proponents praised it as a necessary push for accountability in an industry often criticized for profit-driven pricing.
Legacy and Impact
While the memorandum raised public awareness about drug pricing, its practical impact was limited. Legal challenges stalled enforcement, and the Biden administration later shifted focus to other cost-cutting measures, such as Medicare price negotiation under the Inflation Reduction Act. Nonetheless, the policy underscored ongoing debates about transparency in healthcare and the role of government in regulating pharmaceutical advertising.
